PRESS RELEASES

• Promentis Pharmaceuticals Commences Phase 1 Study for SXC-2023 Targeting Neuropsychiatric Disorders

  November 20, 2017
• Promentis Pharmaceuticals to Present at Society for Neuroscience Meeting

  November 10, 2017
• Promentis Pharmaceuticals, Inc. Announces $26M Series C Financing and Elects Four New Board Members

  March 30, 2017
• Promentis Pharmaceuticals Raises Nearly $3 Million in Series B Financing

  January 21, 2014